The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Next Steps for Cardiome: activated Protein C Program will Seek Other Funding

Update: Cardiome extended its tender offer to allow time to digest the announcement below. Expiry is now October 13th.

When Cardiome (NASDAQ: CRME) (TSX: COM) announced its $27.5 million share buy-back program, the In Vivo Blog noted an earlier comment from its CEO, Doug Janzen, saying that Cardiome doesn’t “believe in the risks of building [its] own pipeline at this point.”

Well, it appears he meant it.  Cardiome has been developing its GED-aPC program via a subsidiary company, but has now decided that the drug “will be funded externally from Cardiome.”  The idea is that

“next steps for the program will be focused on finding external investors and/or partners to assist in future development of the asset.”

Also, Dr. Charles Fisher, CMO and EVP, Clinical & Regulatory Affairs, will be leaving the company and continuing as “a consultant to Cardiome.”

GED-aPC is a recombinant human activated Protein C (aPC) analog with a “broad” range of potential uses.

Bookmark and Share

About these ads

One response to “Next Steps for Cardiome: activated Protein C Program will Seek Other Funding

  1. Pingback: Twitter Trackbacks for Next Steps for Cardiome: activated Protein C Program will Seek Other Funding « The Cross-Border Biotech Blog [crossborderbiotech.ca] on Topsy.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers